Aim of the study~To assess the difference in patients' clinical status improvement between patients receiving remdesivir alone and patients receiving remdesivir and lopinavir/ ritonavir.~To detect time to improvement in oxygenation among both groups.~To detect duration of hospitalization and mortality rate in both groups.~To detect incidence and duration of mechanical ventilation in both treatment arms.~To monitor of adverse events of both drugs.
Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received remdesivir alone with patients who received remdesivir in combination with lopinavir/ ritonavir in addition to standard management.